Galecto, Inc.
(NASDAQ : GLTO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -1.62%162.540.7%$1033.00m
MRKMerck & Co., Inc. -0.69%76.700.7%$980.80m
LLYEli Lilly & Co. -1.17%219.611.1%$901.65m
PFEPfizer Inc. -1.56%38.870.9%$887.27m
ABBVAbbVie, Inc. -1.45%113.231.9%$722.57m
BMYBristol-Myers Squibb Co. -0.67%66.321.0%$618.26m
AZNAstraZeneca Plc -0.95%57.801.2%$393.83m
ANVSAnnovis Bio, Inc. 3.94%93.600.0%$318.49m
OGN -3.45%30.380.0%$316.96m
NVSNovartis AG -1.09%93.120.2%$179.87m
GSKGlaxoSmithKline Plc -1.85%39.820.2%$149.40m
NOVNNovan, Inc. 0.74%10.935.8%$140.92m
ORPHOrphazyme A/S -48.42%7.510.0%$121.95m
BTXBrooklyn ImmunoTherapeutics, Inc. 12.13%17.2012.4%$106.49m
CNSTConstellation Pharmaceuticals, Inc. -0.18%33.760.0%$104.65m

Company Profile

Galecto, Inc. operates as a clinical-stage biotechnology company developing therapeutics which are designed to target the biological processes to treat fibrotic and related diseases including cancer. Its product portfolio includes GB0139, GB1211, GB2064, and GB1211. The company was founded by Ulf Nilsson, Hakon Leffler, Tariq Sethi, and Hans T. Schambye in 2011 and is headquartered in Boston, MA.